We are all working together toward one goal in health while navigating the uncertainty of COVID-19. Rest assured that BD is committed to helping you determine the best solutions across the continuum of care now and in the future as needs surrounding the pandemic continue to evolve.
The average hospital length of stay (LOS) in the U.S. is 5.5 days1, while the median LOS of COVID-19 survivors is 10 to 13 days2
The average hospital length of stay (LOS) in the U.S. is 5.5 days1, while the median LOS of COVID-19 survivors is 10 to 13 days2
Almost 15% of patients hospitalized with COVID-19 required renal replacement therapy (RRT)3
The U.S. government has purchased sufficient COVID-19 vaccine doses to vaccinate 300 million people4
The U.S. government has purchased sufficient COVID-19 vaccine doses to vaccinate 300 million people4
Key challenges your facility may be facing
As COVID-19 vaccinations accelerate and researchers continue pursuing novel vaccines and treatments, BD is responding with a full suite of medication delivery devices to meet the needs of each potential drug. We are continuing to work with the U.S. government to understand needs, scaling up production and ensuring supply availability for safe administration of vaccines.
Selecting the most appropriate device to extend dwell time and reduce catheter restarts
Shown to preserve sites for longer and is designed to protect patients by reducing the risk of complications and restarts*5,6
Provides power injection and blood draw capability, indicated for up to 29 days dwell-time for longer-term therapy
Provides reliable vascular access with multiple lumen options and smaller diameters*** for short and long term infusion therapy.
Offers kink resistance and a third power-injectable lumen for multiple therapies for patients in need of dialysis
Helping to reduce complications
An FDA-approved dual antiseptic of 2% CHG† and 70% IPA‡ that kills bacteria more effectively than single agents, providing both immediate and persistent activity 7,8
An integrated extension tubing and stabilization platform reduces the risk of dislodgment and related complications §5,6
The only needle-free connector proven to reduce CLABSIs.
Eliminates the need for chest X-rays¶ and helps the clinician clear the line, enabling immediate therapy use# **††
Align with recommendations from The Joint Commission and the Infusion Nurses Society (INS) to use a cart or kit that contains all necessary supplies 9,10
An integrated approach for vascular access device selection, placement, and care designed to help reduce vascular access related complications, which may lead to improved patient care.
Minimizing patient and clinician exposure
Shown to preserve sites for longer and designed to protect patients by reducing the risk of complications and restarts 5,6
Sheathes the ultrasound probe, helping to reduce the level of contamination and the risk of infection
A closed-system drug transfer device (CSTD) designed with no inlets or air exchange for completely airtight hazardous drug transfers
We are:
The COVID-19 pandemic has heightened clinicians’ awareness of the potential risks of exposure to bloodborne pathogens when starting and managing peripheral IV catheters (PIVCs).
* Compared to an open system
† Chlorhexidine gluconate
‡ Isopropyl alcohol
§ Compared to B. Braun Introcan Safety® Catheter with Bard Statlock® IV Ultra Stabilization Device
‖ The BD Max needle-free connector technology includes the BD MaxPlus™ Needle-free Connector and the BD MaxZero™ Needle-free Connector.
¶ For CVAD tip placement confirmation of approaches from the superior vena cava.
# When compared to traditional PICC placement methods of blind placement and chest X-ray (CXR).
** Company sponsored study comparing Sherlock 3CGTM TCS on adult patients against historical PICC placement standard of care for blind insertion by a CXR for tip confirmation. Data on file.
†† Reduced cost based on post-hoc exploratory analysis suggesting the costs between the two placement processes are different.
*** Comparison in relation to Bard PowerPICC™ Catheters
BD-23877 (05/21)
